Endo up 3% premarket on FDA OK of generic Orafin

Endo International (NASDAQ:ENDP) is up 3% premarket on light volume in reaction to the FDA nod for subsidiary Endo Ventures partner’s Novitium Pharma’s generic version of Swedish Orphan Biovitrum’s (OTCPK:BIOVF) Orafin (nitisinone capsules) for the treatment of hereditary tyrosinemia type 1 (elevated levels of tyrosine in the blood).

Endo unit Par Pharmaceuticals will distribute to specialty pharmacies starting this month.

According the Swedish Orphan Biovitrum, global sales of Orafin are ~$85M.

https://seekingalpha.com/news/3496695-endo-3-percent-premarket-fda-ok-generic-orafin